ArticleAlzheimer's & dementia (New York, N. Y.)2017
Optimizing the preclinical Alzheimer's cognitive composite with semantic processing: The PACC5.
Article in Alzheimer's & dementia (New York, N. Y.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 214 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
214 citing papers in PubMed, 2 syntheses or guidelines pooled it, 299 citations in OpenAlex.
- Cross-sectional associations of amyloid burden with semantic cognition in older adults without dementia: A systematic review and meta-analysis.Mechanisms of ageing and development · 2020Pooled it
- Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis.Alzheimer's research & therapy · 2019Pooled it
- A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Trial
- Baseline cognition and demographic, lifestyle, and cardiovascular risk factors in US POINTER.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Trial
- Correlation between changes in apathy and cognition in Alzheimer's disease associated apathy: Analysis of the Apathy in Dementia Methylphenidate Trial 2 (ADMET 2).International psychogeriatrics · 2025Trial
- Meditation dosage predicts self- and teacher-perceived responsiveness to an 18-month randomised controlled trial.Scientific reports · 2024Trial
- Trial
- Effects of Meditation Training and Non-Native Language Training on Cognition in Older Adults: A Secondary Analysis of a Randomized Clinical Trial.JAMA network open · 2023Trial
- Effects of a mindfulness-based versus a health self-management intervention on objective cognitive performance in older adults with subjective cognitive decline (SCD): a secondary analysis of the SCD-Well randomized controlled trial.Alzheimer's research & therapy · 2022Trial
- Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients.Alzheimer's research & therapy · 2022Trial
- DTI-ALPS as a Biomarker of Small Vessel Disease Progression and Amyloid-β in Normal Aging: A 3-Year Longitudinal Study.Human brain mapping · 2026Article
- Are the factors associated with cognitive performance generalizable across cohorts?NeuroImage. Clinical · 2026Article
- Associations of physical fitness with brain structure, pathology and cognition in cognitively normal older adults.npj aging · 2026Article
- Astrocyte reactivity modifies the effects of locus coeruleus norepinephrine-related dysfunction on tau and its impact on cognition.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Group-level versus individualized approaches for capturing tau PET changes and clinical progression in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Disruption of temporo-parietal network in Alzheimer's disease and its association with memory impairment.Alzheimer's research & therapy · 2026Observational
- Joint trajectories of brain atrophy, white matter hyperintensities and cognition quantify brain maintenance.Nature communications · 2026Article
- Theoretical and practical challenges for capturing reserve and resilience in aging and Alzheimer's disease: A narrative review.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Review
- Smartphone-based detection of subtle memory decline in prodromal Alzheimer's disease.NPJ digital medicine · 2026Article
- The Role of Clinical, Plasma, and Imaging Biomarkers in Assessing Future Dementia Risk in Individuals With Subjective Cognitive Decline.Neurology · 2026Observational
154 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
introductionAmyloid-related decline in semantic memory was recently shown to be observable in the preclinical period of Alzheimer's disease. Cognitive composites designed to be sensitive to cognitive change in preclinical Alzheimer's disease (e.g., preclinical Alzheimer's cognitive composite [PACC]) and currently used in secondary prevention trials do not currently integrate measures of semantic processing. Our objective was to determine whether a standard semantic measure (i.e., category fluency [CAT] to animals, fruits, and vegetables) adds independent information above and beyond Aβ-related decline captured by the PACC.
methodsClinically normal older adults from the Harvard Aging Brain Study were identified at baseline as Aβ+ (n = 70) or Aβ- (n = 209) using Pittsburgh compound B-positron emission tomography imaging and followed annually with neuropsychological testing for 3.87 ± 1.09 years. The relationships between PACC, CAT, and variations of the PACC including/excluding CAT were examined using linear mixed models controlling for age, sex, and education. We additionally examined decline on CAT by further grouping Aβ+ participants into preclinical stage 1 and stage 2 on the basis of neurodegeneration markers.
resultsCAT explained unique variance in amyloid-related decline, with Aβ+'s continuing to decline relative to Aβ-'s in CAT even after controlling for overall PACC decline. In addition, removal of CAT from the PACC resulted in a longitudinal Aβ+/- effect size reduction of 20% at 3-year follow-up and 12% at 5-year follow-up. Finally, both stage 1 and stage 2 participants declined on CAT in comparison with stage 0, suggesting CAT declines early within the preclinical trajectory.
conclusionAddition of CAT to the PACC provides unique information about early cognitive decline not currently captured by the episodic memory, executive function, and global cognition components and may therefore improve detection of early Aβ-related cognitive decline.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.